InfuSystem (INFU) Stock Price, News & Analysis

Company Overview

InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem’s offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards.

In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions. By integrating connected infusion pumps with data analytics and telehealth platforms, the company enables healthcare providers to monitor therapy progress, optimize patient outcomes and improve staff efficiency. This end-to-end model supports a broad range of IV infusion therapies, including chemotherapy, pain management and antibiotic administration.

Headquartered in St. Petersburg, Florida, InfuSystem was founded in the late 1980s and has grown to serve healthcare facilities across the United States and select international markets. The company is governed by a board of directors and a management team with deep experience in medical device services and healthcare operations. InfuSystem continues to invest in technology and infrastructure to meet evolving regulatory requirements and the shifting landscape of outpatient care.

Key Stats

• Today's Range: $9.97 to $10.13
• 50-Day Range: $5.41 to $10.78
• 52-Week Range: $4.61 to $11.04
• Volume: 112,730 shs
• Average Volume: 179,926 shs
• Market Capitalization: $205.69 million
• P/E Ratio: 167.86
• Dividend Yield: N/A
• Price Target: $12.50
• Consensus Rating: Strong Buy

InfuSystem Stock Analysis - MarketRank™

InfuSystem scored higher than 67% of companies evaluated by MarketBeat, and ranked 357th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Strong Buy

Upside Potential

InfuSystem has a consensus price target of $12.50, representing about 24.1% upside from its current price of $10.07.

Amount of Analyst Coverage

InfuSystem has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 106.67%

Earnings Growth

Earnings for InfuSystem are expected to grow by 106.67% in the coming year, from $0.15 to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InfuSystem is 167.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.45.

Price to Earnings Ratio vs. Sector

The P/E ratio of InfuSystem is 167.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 74.67.

Price to Book Value per Share Ratio

InfuSystem has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.89% of the float of InfuSystem has been sold short.

Short Interest Ratio / Days to Cover

InfuSystem has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InfuSystem has recently increased by 1.80%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InfuSystem does not currently pay a dividend.

Dividend Growth

InfuSystem does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.89% of the float of InfuSystem has been sold short.

Short Interest Ratio / Days to Cover

InfuSystem has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InfuSystem has recently increased by 1.80%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.65

News Sentiment

InfuSystem has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for InfuSystem this week, compared to 1 article on an average week.

Search Interest

10 people have searched for INFU on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.

MarketBeat Follows

5 people have added InfuSystem to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, InfuSystem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,622.00 in company stock.

Percentage Held by Insiders

10.20% of the stock of InfuSystem is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.13% of the stock of InfuSystem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INFU Stock Analysis - Frequently Asked Questions

How have INFU shares performed this year?

InfuSystem's stock was trading at $8.45 on January 1st, 2025. Since then, INFU stock has increased by 19.2% and is now trading at $10.07.

How were InfuSystem's earnings last quarter?

InfuSystem Holdings, Inc. (NYSE:INFU) announced its earnings results on Thursday, November, 7th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.08. The firm had revenue of $35.32 million for the quarter, compared to analyst estimates of $35.50 million. InfuSystem had a trailing twelve-month return on equity of 2.78% and a net margin of 1.12%.

Who are InfuSystem's major shareholders?

Top institutional investors of InfuSystem include AWM Investment Company Inc. (6.23%), Minerva Advisors LLC (4.87%), First Eagle Investment Management LLC (4.33%) and Geode Capital Management LLC (1.06%). Insiders that own company stock include Richard Dilorio, Carrie Lachance, Christopher R Sansone, Scott Shuda, Barry G Steele, Paul Andrew Gendron, R Rimmy Malhotra, Addam Chupa, Ralph F Boyd Jr, Kenneth D Eichenbaum and Gregg Owen Lehman.
View institutional ownership trends.

How do I buy shares of InfuSystem?

Shares of INFU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InfuSystem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InfuSystem investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 9/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:INFU
• Previous Symbol: NYSE:INFU
• CIK: 1337013
• Web: www.infusystem.com
• Phone: (248) 291-1210
• Fax: 800-455-4338
• Employees: 410
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InfuSystem: $12.50
• High Price Target: $13.00
• Low Price Target: $12.00
• Potential Upside/Downside: +24.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 4.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.23
• Trailing P/E Ratio: 167.58
• Forward P/E Ratio: 67.05
• P/E Growth: N/A
• Net Income: $870 thousand
• Net Margins: 1.12%
• Pretax Margin: 2.65%
• Return on Equity: 2.78%
• Return on Assets: 1.41%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.98
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $139.89 million
• Price / Sales: 1.47
• Cash Flow: $0.79 per share
• Price / Cash Flow: 12.79
• Book Value: $2.47 per share
• Price / Book: 4.07

Miscellaneous

• Outstanding Shares: 20,426,000
• Free Float: 19,095,000
• Market Cap: $205.42 million
• Optionable: Optionable
• Beta: 1.82